Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • EP full-text search
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Technology insight reports
    • Data
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Technology platforms
      • Overview
      • Plastics in transition
      • Water innovation
      • Space innovation
      • Technologies combatting cancer
      • Firefighting technologies
      • Clean energy technologies
      • Fighting coronavirus
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
    Image
    Plastics in Transition

    Technology insight report on plastic waste management

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • Find a professional representative
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact with us on your files
      • Online Filing & fee payment outages
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Find out how the Unitary Patent can enhance your IP strategy

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • Guidelines
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National measures relating to the Unitary Patent
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
    Image
    Law and practice scales 720x237

    Keep up with key aspects of selected BoA decisions with our monthly "Abstracts of decisions”

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • European Inventor Network
      • The 2024 event
    • Young Inventors Prize
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
      • The 2025 event
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Water-related technologies
      • CodeFest
      • Green tech in focus
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    From ideas to inventions: tune into our podcast for the latest in tech and IP

  • Learning

    Learning

    The European Patent Academy – the point of access to your learning

    Go to overview 

    • Overview
    • Learning activities and paths
      • Overview
      • Learning activities
      • Learning paths
    • EQE and EPAC
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Overview
      • Business and IP managers
      • EQE and EPAC Candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)
    Image
    Patent Academy catalogue

    Have a look at the extensive range of learning opportunities in the European Patent Academy training catalogue

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Overview
      • Communiqués
      • Calendar
      • Documents and publications
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Sustainability at the EPO
      • Overview
      • Environmental
      • Social
      • Governance and Financial sustainability
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Overview
      • Technologies
      • Innovation actors
      • Policy and funding
      • Tools
      • About the Observatory
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Sustainable Procurement Policy
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
      • "Long Night"
    Image
    Patent Index 2024 keyvisual showing brightly lit up data chip, tinted in purple, bright blue

    Track the latest tech trends with our Patent Index

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
    • Go back
    • New to patents
  • New to patents
    • Go back
    • Your business and patents
    • Why do we have patents?
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Is it patentable?
    • Are you first?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Release notes
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • EP full-text search
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Technology insight reports
    • Data
      • Go back
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
        • Boards of Appeal decisions
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server web service
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Technology platforms
      • Go back
      • Overview
      • Plastics in transition
        • Go back
        • Overview
        • Plastics waste recovery
        • Plastics waste recycling
        • Alternative plastics
      • Innovation in water technologies
        • Go back
        • Overview
        • Clean water
        • Protection from water
      • Space innovation
        • Go back
        • Overview
        • Cosmonautics
        • Space observation
      • Technologies combatting cancer
        • Go back
        • Overview
        • Prevention and early detection
        • Diagnostics
        • Therapies
        • Wellbeing and aftercare
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
    • Helpful resources
      • Go back
      • Overview
      • First time here?
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
          • Introductory brochures
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Exchange data with us using an API
          • Go back
          • Release notes
      • Get access
        • Go back
        • Overview
        • Release notes
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact with us on your files
        • Go back
        • Release notes
      • Online Filing & fee payment outages
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Overview
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • Guidelines
        • Go back
        • Overview
        • EPC Guidelines
        • PCT-EPO Guidelines
        • Unitary Patent Guidelines
        • Guidelines revision cycle
        • Consultation results
        • Summary of user responses
        • Archive
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
        • Go back
        • Travaux préparatoires to UP and UPC
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • About the award
      • Categories and prizes
      • Meet the inventors
      • Nominations
      • European Inventor Network
        • Go back
        • 2024 activities
        • 2025 activities
        • Rules and criteria
        • FAQ
      • The 2024 event
    • Young Inventors Prize
      • Go back
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
      • The 2025 event
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Water-related technologies
      • CodeFest
        • Go back
        • CodeFest Spring 2025 on classifying patent data for sustainable development
        • Overview
        • CodeFest 2024 on generative AI
        • CodeFest 2023 on Green Plastics
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • Learning activities and paths
      • Go back
      • Overview
      • Learning activities: types and formats
      • Learning paths
    • EQE and EPAC
      • Go back
      • Overview
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Compendium
          • Go back
          • Overview
          • Paper F
          • Paper A
          • Paper B
          • Paper C
          • Paper D
          • Pre-examination
        • Candidates successful in the European qualifying examination
        • Archive
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventor's handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
          • Competition and market potential
          • Assessing the risk ahead
          • Proving the invention
          • Protecting your idea
          • Building a team and seeking funding
          • Business planning
          • Finding and approaching companies
          • Dealing with companies
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • Business decision-makers
          • IP professionals
          • Stakeholders of the Innovation Ecosystem
      • EQE and EPAC Candidates
        • Go back
        • Overview
        • Paper F brain-teasers
        • Daily D questions
        • European qualifying examination - Guide for preparation
        • EPAC
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Modular IP Education Framework (MIPEF)
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
        • PATLIB Knowledge Transfer to Africa
          • Go back
          • Core activities
          • Stories and insights
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Official celebrations
      • Overview
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Go back
      • Overview
      • Communiqués
        • Go back
        • 2024
        • Overview
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
        • Go back
        • Driver 1: People
        • Driver 2: Technologies
        • Driver 3: High-quality, timely products and services
        • Driver 4: Partnerships
        • Driver 5: Financial sustainability
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Sustainability at the EPO
      • Go back
      • Overview
      • Environmental
        • Go back
        • Overview
        • Inspiring environmental inventions
      • Social
        • Go back
        • Overview
        • Inspiring social inventions
      • Governance and Financial sustainability
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Dynamic Purchasing System (DPS) publications
      • Sustainable Procurement Policy
      • About eTendering
      • Invoicing
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Quality Action Plan
        • Quality dashboard
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
        • Integrated management at the EPO
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
        • Surveys
          • Go back
          • Overview
          • Detailed methodology
          • Search services
          • Examination services, final actions and publication
          • Opposition services
          • Formalities services
          • Customer services
          • Filing services
          • Key Account Management (KAM)
          • Website
          • Archive
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Go back
      • Overview
      • Technologies
        • Go back
        • Overview
        • Innovation against cancer
        • Assistive robotics
        • Space technologies
      • Innovation actors
        • Go back
        • Overview
        • Startups and SMEs
          • Go back
          • Overview
          • Publications
        • Research universities and public research organisations
      • Policy and funding
        • Go back
        • Overview
        • Financing innovation programme
          • Go back
          • Overview
          • Our studies on the financing of innovation
          • EPO initiatives for patent applicants
          • Financial support for innovators in Europe
        • Patents and standards
          • Go back
          • Overview
          • Publications
          • Patent standards explorer
      • Tools
        • Go back
        • Overview
        • Deep Tech Finder
      • About the Observatory
        • Go back
        • Overview
        • Work plan
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2023
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • 50 years of the EPC
          • Strategic key performance indicators
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
        • Go back
        • Insight into computer technology and AI
        • Insight into clean energy technologies
        • Statistics and indicators
          • Go back
          • European patent applications
            • Go back
            • Key trend
            • Origin
            • Top 10 technical fields
              • Go back
              • Computer technology
              • Electrical machinery, apparatus, energy
              • Digital communication
              • Medical technology
              • Transport
              • Measurement
              • Biotechnology
              • Pharmaceuticals
              • Other special machines
              • Organic fine chemistry
            • All technical fields
          • Applicants
            • Go back
            • Top 50
            • Categories
            • Women inventors
          • Granted patents
            • Go back
            • Key trend
            • Origin
            • Designations
      • Data to download
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Go back
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
        • Go back
        • Catalyst lab & Deep vision
          • Go back
          • Irene Sauter (DE)
          • AVPD (DK)
          • Jan Robert Leegte (NL)
          • Jānis Dzirnieks (LV) #1
          • Jānis Dzirnieks (LV) #2
          • Péter Szalay (HU)
          • Thomas Feuerstein (AT)
          • Tom Burr (US)
          • Wolfgang Tillmans (DE)
          • TerraPort
          • Unfinished Sculpture - Captives #1
          • Deep vision – immersive exhibition
          • Previous exhibitions
        • The European Patent Journey
        • Sustaining life. Art in the climate emergency
        • Next generation statements
        • Open storage
        • Cosmic bar
      • "Long Night"
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Information from the Boards of Appeal
    • Procedure
    • Oral proceedings
    • About the Boards of Appeal
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2025
      • Archive
    • Annual list of cases
    • Communications
    • Annual reports
      • Go back
      • Overview
    • Publications
      • Go back
      • Abstracts of decisions
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Patent Knowledge Products and Services
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Glossary
    • RSS feeds
Board of Appeals
Decisions

Recent decisions

Overview
  • 2025 decisions
  • 2024 decisions
  • 2023 decisions
  1. Home
  2. T 0402/12 (Neoadjuvant therapy/GENENTECH) 17-03-2016
Facebook X Linkedin Email

T 0402/12 (Neoadjuvant therapy/GENENTECH) 17-03-2016

European Case Law Identifier
ECLI:EP:BA:2016:T040212.20160317
Date of decision
17 March 2016
Case number
T 0402/12
Petition for review of
-
Application number
00928916.6
IPC class
A61K 39/395
A61P 35/00
Language of proceedings
EN
Distribution
NO DISTRIBUTION (D)

Download and more information:

Decision in EN 385.81 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

Treatment with anti-ErbB2 antibodies

Applicant name
Genentech, Inc.
Opponent name
Teva Pharmaceutical Industries Ltd.
Board
3.3.04
Headnote
-
Relevant legal provisions
European Patent Convention Art 56
European Patent Convention Art 115
Keywords

Inventive step - main request (no)

Inventive step - auxiliary request (no)

Observations by third parties - relevant (no)

Catchword
-
Cited decisions
T 1756/11
Citing decisions
-

I. The appeal was lodged by the patent proprietor (hereinafter "the appellant") against the decision of the opposition division to revoke European patent No. 1 187 632. The title of the patent is "Treatment with anti-ErbB2 antibodies".

II. The patent was opposed under Article 100(a) EPC on the grounds of lack of novelty and inventive step and under Article 100(b) EPC.

III. The impugned decision dealt with a main request and an auxiliary request both submitted during the oral proceedings. The opposition division held that the subject-matter of claim 1 of both requests lacked an inventive step.

IV. With its statement of grounds of appeal the appellant submitted a main and an auxiliary request which were both identical to the claim requests underlying the impugned decision. The appellant further submitted arguments why the opposition division had erred in its decision that the main and auxiliary requests did not involve an inventive step.

Claim 1 of the main request reads:

"1. Use of an anti-ErbB2 antibody for the manufacture of a medicament for treating a human patient diagnosed with a tumour in which ErbB2 protein is expressed, wherein the medicament is for treating the patient prior to steps of surgical removal of the tumour and treatment of the patient after the surgical removal of the tumour with anti-ErbB2 antibody and/or a chemotherapeutic agent."

Claim 1 of the auxiliary request reads:

"1. Use of an anti-ErbB2 antibody for the manufacture of a medicament for treating a human patient diagnosed with a tumour in which ErbB2 protein is expressed, wherein the medicament is for treating the patient prior to steps of surgical removal of the tumour and treatment of the patient after the surgical removal of the tumour with anti-ErbB2 antibody and/or a chemotherapeutic agent, wherein the patient is further treated with one or more chemotherapeutic agents prior to the surgical removal of the tumour."

V. In reply to the statement of grounds of appeal, the opponent (hereinafter "the respondent") submitted arguments why the subject-matter of claims 1 of both requests lacked an inventive step.

VI. Third party observations were filed pursuant to

Article 115 EPC. The appellant replied to the board's invitation to comment on the observations by submitting inter alia that they were "without substance".

VII. Oral proceedings before the board were held on 17 March 2016. At the end of the oral proceedings the chairwoman announced the board's decision.

VIII. The following documents are cited in this decision:

D3: Valero V., Seminars in Oncology 1998, 25(2), 36-41

D4: Perez E.A., The Oncologist, 1998, 3, 373-389

D5: McNeil C., J. Natl. Cancer Inst. 1998, 90(12), 882-883

IX. The appellant's arguments may be summarised as follows:

Main request

Inventive step (Article 56 EPC)

Document D3 represented the closest prior art. It disclosed a treatment regimen of administering chemotherapeutic agents prior to and after the surgical removal of breast cancer. The subject-matter of claim 1 comprised several embodiments. One of them differed from the regimen disclosed in document D3 in that a combination of anti-ErbB2 antibodies and chemotherapeutic agents was administered prior to the surgical removal of tumours expressing the ErbB2 protein instead of administering the chemotherapeutic agents alone. The technical effect associated with this difference was an extended survival time of the patients treated. The objective technical problem was thus the provision of means for an improved neoadjuvant therapy for human ErbB2-expressing tumours.

Document D3 also reported that an anti-ErbB2 antibody was administered either alone in a therapy of stage IV breast cancer or together with chemotherapeutic agents in a first-line therapy for metastatic disease (page 39, column 2, third paragraph, to page 40, column 1, first paragraph). However, since both of these disorders indicated to the skilled person a late-stage of breast cancer where surgery was not a therapeutic option, the application of antibodies and chemotherapeutic agents before surgery was not suggested by this disclosure.

Document D3 further proposed that the role of anti-ErbB2 antibody-based therapies "in conjunction with primary chemotherapy should be assessed in patients with early breast cancer" (page 40, column 1, first paragraph). However, since chemotherapy differed fundamentally from an antibody-based therapy, the skilled person would not have understood the term "primary chemotherapy" in this context to refer to an anti-ErbB2 antibody-based therapy. Hence, the skilled person would have inferred from this statement that document D3 proposed to assess treatment regimens based on chemotherapy before surgery, followed by post-surgical administration of a combination of anti-ErbB2 antibodies and chemotherapeutic agents to prevent metastases. The opposition division in its decision had come to a different interpretation of this statement in document D3 on the basis of hindsight, i.e. it had read this statement in the light of the invention. Document D3 therefore disclosed no pointers for the skilled person to administer a combination of chemotherapeutic agents and anti-ErbB2 antibodies instead of chemotherapeutic agents alone, prior to the surgical removal of the tumour.

The teaching of the other cited prior art documents likewise did not motivate the skilled person to use anti-ErbB2 antibodies in a pre-surgical treatment regimen in patients with breast cancer. Document D5, for example, disclosed a clinical study which showed that the administration of an anti-ErbB2 antibody (Herceptin**(TM)) extended the remission time in metastatic, i.e. stage IV, breast cancer patients and suggested in view of this result that "The most logical place to use this drug will likely be earlier and up front". However, the only ongoing trial mentioned in document D5 for testing the prediction that Herceptin**(TM) in combination with chemotherapeutic agents was effective in the therapy of earlier stages of the disease related to patients with a stage III breast cancer which would have indicated to the skilled person - like the stage IV disclosed in document D3 - an advanced tumour stage with unclear surgical treatment options. Hence, the skilled person would not have inferred from this statement in document D5 that anti-ErbB2 antibodies should be applied in a pre-surgical treatment regimen.

Thus, the subject-matter of claim 1 met the requirements of Article 56 EPC.

X. The respondent's arguments may be summarised as follows:

Main request

Inventive step (Article 56 EPC)

Document D3 represented the closest prior art. The document reported on present and future strategies for the improvement of neoadjuvant therapies in the management of breast cancer. Although the disclosed standard agents for neoadjuvant therapy in locally advanced breast cancer (LABC) patients were chemotherapeutics, the document also reported that anti-ErbB2 antibodies either alone or in combination with a chemotherapeutic agent could be promising anti-breast cancer therapeutic agents. In this context the document proposed that the role of antibody-based therapies "in conjunction with primary chemotherapy should be assessed in patients with early breast cancer". "Primary chemotherapy" was a synonym for pre-surgical or neoadjuvant chemotherapy. Although an antibody-based therapy would not necessarily be considered as a chemotherapy, the skilled person would nevertheless have inferred from the teaching of document D3 as a whole - dealing exclusively with the improvement of pre-surgical therapies in breast cancer - that the proposal in fact meant inter alia assessing the role of a combination of anti-ErbB2 antibodies and chemotherapeutic agents in pre-surgical treatment regimens.

Document D5 disclosed that the administration of a combination of anti-ErbB2 antibodies and chemotherapeutic agents had a synergistic anti-cancer activity compared to the administration of chemotherapeutic agents alone, thereby improving the therapy of metastatic, i.e. late-stage, breast cancer. Document D5 suggested, in view of this effect, an "earlier and up front" administration of both of these agents in the therapy of breast cancer. A pre-surgical treatment regimen in LABC patients was an earlier and up-front therapy, and accordingly the teaching of document D5 motivated the skilled person to administer anti-ErbB2 antibodies in addition to chemotherapeutic agents - instead of chemotherapeutic agents alone, as disclosed in document D3 - to improve pre-surgical breast cancer treatment regimens.

Thus, the subject-matter of claim 1 was obvious in the light of the teaching of document D3 either alone or when combined with that of document D5 and therefore did not meet the requirements of Article 56 EPC.

XI. The appellant requested that the decision under appeal be set aside and that a patent be maintained on the basis of the main request or the auxiliary request, both filed with the statement of grounds of appeal.

The respondent requested that the appeal be dismissed.

Main request

Introduction to the invention

1. The therapeutic application underlying the invention relates to ErbB2-expressing tumours in human patients. The ErbB2 protein is a cell surface-exposed growth-factor receptor which is over-expressed in about 25% to 30% of human breast cancer patients. It is also referred to in the art as HER2/neu and p185**(HER2) (see e.g. patent in suit, paragraph [0002], and document D5, page 1, third paragraph).

2. Furthermore, the pre-surgical or pre-operative administration of therapeutic agents in tumour therapy is commonly also referred to as neoadjuvant or primary therapy (see e.g. document D3, page 36, column 1, first paragraph), while their post-surgical or post-operative administration is also referred to as adjuvant therapy (see e.g. document D3, page 37, column 1, second paragraph).

Claim construction

3. The subject-matter of claim 1 concerns the use of anti-ErbB2 antibodies for the manufacture of a medicament in the therapy of human patients positively diagnosed for ErbB2-expressing tumours by administering the medicament "prior to steps of surgical removal of the tumour and treatment of the patient after the surgical removal of the tumour with anti-ErbB2 antibody and/or a chemotherapeutic agent". It was common ground between the parties that the invention as defined in claim 1 comprised several alternative treatment regimens. The administration of a combination of anti-ErbB2 antibodies and chemotherapeutic agents prior to the surgical removal of the tumour, followed by post-surgical administration of solely chemotherapeutic agents, is one of them and will be considered in the following.

Inventive step (Article 56 EPC)

Closest prior art

4. The parties considered that document D3 represented the closest prior art and the board has no reason to differ.

5. Document D3 is a review article dealing with current and future directions of neoadjuvant, i.e. pre-surgical (see point 2 above), therapy in human breast cancer. It discloses that this therapy was initially introduced in patients with locally advanced breast cancer (LABC) with the main purpose of eliminating distant micrometastatic tumours and that it now forms an integral part in the management of the disease (see title, page 36, column 1, first paragraph, and column 2, second paragraph). As an example of a treatment regimen in LABC patients the document discloses that patients receive a first chemotherapy, prior to the surgical removal of the tumour, followed by a second post-surgical chemotherapy (see page 39, column 1, first paragraph).

Document D3 also reports on "New biologic-genetic therapies" in breast cancer patients consisting inter alia of the administration of a combination of anti-HER2/neu, i.e. anti-ErbB2, antibodies and chemotherapeutic agents (see point 1 above and page 39, column 2, third paragraph, to page 40, column 1, first paragraph, of document D3). It is not disclosed, however, that the therapy involves the surgical removal of the tumour.

6. Thus, the board considers that the regimen disclosed in document D3 of administering chemotherapeutic agents prior to and after the surgical removal of a tumour in patients with a diagnosed breast cancer represents the closest prior art for the embodiment of claim 1 under consideration (see point 3 above).

Technical problem and solution

7. This embodiment differs from that of the closest prior art by the pre-surgical administration of both anti-ErbB2 antibodies and chemotherapeutic agents instead of the pre-surgical administration of chemotherapeutic agents alone. The technical effect associated with this difference is a further extension of patient survival time.

8. Thus, the objective technical problem to be solved is formulated as the provision of an improved pre-surgical treatment regimen in the therapy of human ErbB2-expressing cancer.

9. The board is satisfied that the embodiment of claim 1 under consideration is a solution to this problem.

Obviousness

10. It remains to be assessed whether the skilled person starting from the treatment regimen of document D3 and faced with the technical problem defined in point 8 above would modify the teaching of document D3 in view of this document either alone or in combination with a teaching in another prior art document so as to arrive at the claimed embodiment under consideration in an obvious manner.

11. Document D3, after summarising the achievements of the current compared to the historic therapy of LABC, discloses that "Although the natural history of LABC was changed by the introduction of systemic therapies, more than 60% of these patients still died of metastatic breast cancer [...], suggesting that there is room for considerable improvement. New research directions in primary chemotherapy [i.e. pre-surgical chemotherapy (see point 2 above); note added by the board] to improve the outcome of patients with breast cancer are priorities in basic and clinical research" (see page 37, column 1, third paragraph).

12. Document D3 then presents several current research directions for improving primary chemotherapy, including "New biologic-genetic therapies" (see page 37, column 1, fourth paragraph and page 39, column 2, third paragraph). It reports in this context on two clinical studies in which the administration of anti-ErbB2 antibodies either alone or in combination with chemotherapeutic agents attained a beneficial therapeutic effect in pre-treated patients with a stage IV breast cancer or in a first-line therapy of patients with metastatic diseases, respectively (see page 39, column 2, third paragraph, to page 40, column 1, first paragraph). "First-line therapy" means that the patients have not received any kind of prior anti-cancer therapy (see e.g. document D4, page 373, column 2, second line). Moreover, it was uncontested that the patients enrolled in both of these studies had a late-stage cancer disease.

In view of the results of the two studies document D3 suggests that "The role of these novel strategies [i.e. therapies based on anti-ErbB2 antibodies either alone or together with chemotherapeutic agents; note added by the board] in conjunction with primary chemotherapy should be assessed in patients with early breast cancer." (see page 39, column 2, third paragraph, to page 40, column 1, first paragraph).

13. In the board's opinion, document D3 thus teaches the skilled person that, because of the high mortality rate of patients with LABC, there is a need for improving the existing pre-surgical treatment regimens based on chemotherapeutic agents. Moreover, since its teaching as a whole focuses exclusively on means for improving pre-surgical treatment regimens (see point 5 above), the skilled person would have inferred from the suggestion in document D3 to assess the role of anti-ErbB2 antibodies either alone or in combination with chemotherapeutic agents "in conjunction with primary chemotherapy" that this means the use of anti-ErbB2 antibodies combined with chemotherapeutic agents in a pre-surgical treatment of patients with early breast cancer.

14. In contrast, the appellant submitted that the passage in document D3 disclosing that "The role of these novel strategies in conjunction with primary chemotherapy should be assessed in patients with early breast cancer" would have been construed by the skilled person as suggesting an improved treatment for LABC patients a regimen consisting of pre-surgical chemotherapy followed by post-surgical therapy based on inter alia the combination of anti-ErbB2 antibodies and chemotherapeutic agents. This was so since the term "chemotherapy" would have been understood by the skilled person not to refer to antibody-based therapies.

Thus, in the appellant's view, the skilled person would have inferred from document D3 that the standard LABC treatment regimen consisting of the administration of chemotherapeutic agents prior to and after the surgical removal of a tumour (see point 6 above) could be improved by leaving the pre-surgical therapy unaltered while altering the post-surgical therapy to include antibodies in addition to the chemotherapeutic agent.

15. In the board's view, if this interpretation of document D3 were adopted, the improvement of the cancer therapy would lie in the post-surgical treatment, because the pre-surgical one is not changed. This would be at odds, however, with the overall teaching of document D3 which, as noted in points 5 and 13 above, is exclusively concerned with new strategies for improving pre-surgical treatment regimens in patients with breast cancer.

16. The appellant argued that a further reason why the passage on pages 39 and 40 of document D3 would not have suggested to the skilled person to administer anti-ErbB2 antibodies together with chemotherapeutic agents in a pre-surgical treatment regimen was that the breast cancer stages of the patients enrolled in the two studies disclosed were too advanced, such that surgery was excluded as a therapeutic option.

17. The board is not convinced by this argument because document D3 explicitly proposes that "The role of these novel strategies in conjunction with primary chemotherapy should be assessed in patients with early breast cancer" (see point 13 above; emphasis added), i.e. in stages of cancer when surgery is an option.

18. Thus, in summary, the board concludes that document D3 would motivate the skilled person to administer a combination of anti-ErbB2 antibodies and chemotherapeutic agents in a pre-surgical treatment regimen of patients with a diagnosed ErbB2-expressing cancer.

19. The appellant in a further line of argument referred to document D5 and its disclosure on page 3 in the second paragraph and in the first sentence of the third paragraph, which reads: "Some of the excitement surrounding Herceptin stems from the probability that the drug, now proven in metastatic breast cancer, will have an impact in other settings. Hope focuses particularly on other stages of breast cancer. "The most logical place to use this drug will likely be earlier and up front. [...].

At least one trial to test the prediction in stage III breast cancer is now being designed [...]."

20. The appellant submitted that the skilled person, in the light of the disclosure in this passage of the "proven" effectiveness of the anti-ErbB2 antibody Herceptin**(TM) in "metastatic breast cancer" and of an ongoing trial with patients in "stage III breast cancer", would have inferred that Herceptin**(TM) could effectively be administered only in late-stages of the disease, i.e. stage III or the metastatic stage of the disease (stage IV), where surgery was not an option. In other words, the skilled person would have been taught by document D5 not to administer the antibody at stages contemplated by claim 1, i.e. stages where surgery was an option.

21. The board does not agree with this interpretation. The cited passage in document D5 discloses that "now" that efficacy was "proven" in "metastatic breast cancer", "hope focuses particularly on other stages", which, logically were stages which were "earlier". The board considers that, in this context, the skilled person would have understood that "earlier" does not only refer to stage III of the cancer disease, but that it in fact refers to all stages which are earlier than the metastatic stage. Therefore, the sentence following the second paragraph reading "At least one trial to test the prediction in stage III breast cancer is now being designed" would not have indicated to the skilled person that necessarily only trials with patients in stage III were ongoing. The statement on page 1, second paragraph of document D5 supports this view. It reads "Plans to test the drug in earlier stage breast cancer are well under way".

22. Thus, in the board's view, the disclosure in document D5 referred to by the appellant would not have discouraged the skilled person from following the suggestion disclosed in document D3 to administer a combination of anti-ErbB2 antibodies and chemotherapeutic agents in a pre-surgical treatment regimen. And all the more so since document D5 discloses that the two agents had a synergistic effect when they were administered in the therapy of metastatic disease (see page 2, second and third paragraphs).

23. Hence, in the light of the observations in points 11 to 22 above, the skilled person would have arrived at the embodiment of claim 1 under consideration (see point 3 above) in an obvious manner in view of the teaching of document D3.

24. Consequently, this embodiment of claim 1 - and hence the main request as a whole - fails to meet the requirements of Article 56 EPC.

Auxiliary request

25. The subject-matter of claim 1 of the auxiliary request differs from that of the main request in that pre-surgical treatment regimens are limited to the administration of a combination of anti-ErbB2 antibodies and chemotherapeutic agents.

26. Accordingly, the invention as defined in claim 1 of the auxiliary request comprises an embodiment which corresponds to the embodiment of claim 1 of the main request considered above (see point 3). However, the board has decided that such an embodiment is obvious in the light of the teaching of document D3 alone (see point 23 above).

27. Consequently, the auxiliary request does not meet the requirements of Article 56 EPC either.

Third party observations (Article 115 EPC)

28. Third party observations were filed during the appeal proceedings.

29. According to established case law, submissions emerging from third party observations filed after expiry of the time limit for filing a notice of opposition are treated by legal fiction as being late (see e.g. decision T 1756/11, point 2.3 of the Reasons). Therefore their admission into the appeal proceedings is at the board's discretion.

30. The appellant submitted that the third party's observations were "without substance" (see section VI). The respondent did not rely on them. The board has thus decided to disregard the third party's observations.

Order

For these reasons it is decided that:

The appeal is dismissed

Footer - Service & support
  • Service & support
    • Website updates
    • Availability of online services
    • FAQ
    • Publications
    • Procedural communications
    • Contact us
    • Subscription centre
    • Official holidays
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
Facebook
European Patent Office
EPO Jobs
Instagram
EuropeanPatentOffice
Linkedin
European Patent Office
EPO Jobs
EPO Procurement
X (formerly Twitter)
EPOorg
EPOjobs
Youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility